Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27513844 | 0.98 | MEN1 (0.33) | MEN1NPC1RAB9AKMT2AAXL | |
| Acetonitrile SCHEMBL27537842 | 0.89 | LRRK2 (0.33) | — | |
| SCHEMBL1188205 | 0.74 | CSNK2A2 (0.30) | — | |
| SCHEMBL30682949 | 0.74 | BRD4 (0.36) | — | |
| Hydrochloric Acid SCHEMBL21683018 | 0.72 | GDA (0.35) | PRKCICYP3A4 | |
| Hydrochloric Acid SCHEMBL29616692 | 0.72 | GDA (0.35) | PRKCICYP3A4 | |
| SCHEMBL15109735 | 0.69 | LRRK2 (0.34) | CYP3A4 | |
| SCHEMBL7165260 | 0.69 | MEN1 (0.47) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL27881430 | 0.69 | ACVR1 (0.33) | — | |
| SCHEMBL352433 | 0.68 | NPC1 (0.36) | MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036736-A | Pyrrolo [2,3-d ] pyrimidine derivative, synthetic method and application | 云南大学 | 2026-05-15 | — | — | CN | claimed |
| CN-118146226-A | Pyrrolo [2,3-d ] pyrimidine compound with nitrogen-containing heterocyclic structure, and preparation method and application thereof | 贵州大学 | 2024-06-07 | — | — | CN | claimed |
| CN-113549077-B | Production process of 4-chloropyrrolo [2,3-d ] pyrimidine | 浙江倍合德制药有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-113549077-A | Production process of 4-chloropyrrolo [2,3-d ] pyrimidine | 浙江倍合德制药有限公司 | 2021-10-26 | — | — | CN | claimed |
| CN-113121539-A | Preparation method of PF06651600 | 江苏艾立康医药科技有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | UNICHEM LABORATORIES LIMITED (IN) | 2020-11-10 | — | — | US | claimed |
| WO-2005016878-A2 | METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| EP-1303516-A1 | IMIDAZOLOPHTHALAZINE DERIVATIVES AS LIGANDS FOR GABA A? RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-04-23 | — | — | EP | claimed |
| WO-2002006285-A1 | IMIDAZOLOPHTHALAZINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-01-24 | — | — | WO | claimed |
| CN-122036736-A | Pyrrolo [2,3-d ] pyrimidine derivative, synthetic method and application | 云南大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-116496219-B | Six-membered and five-membered heterocyclic compound, and pharmaceutical composition and application thereof | 东南大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250215009-A1 | PROCESS FOR MAKING CRYSTALLINE 2-(3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-1-(CYCLOPROPYLSULFONYL)AZETIDIN-3-YL)ACETONITRILE | ELANCO US INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250205157-A1 | TOPICAL RUXOLITINIB FOAM | INCYTE CORPORATION (US) | 2025-06-26 | — | — | US | disclosed |
| WO-1994017803-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1994006438-A1 | ADENOSINE ANALOGUES AND METHOD OF INCREASING ADENOSINE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-31 | — | — | WO | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0496617-A1 | Adenosine kinase inhibitors | GENSIA, INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| US-4968686-A | DECREASED CYTOTOXICITY; CYTOMEGALO AND HERPEX SIMPLEX VIRUSES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1990-11-06 | — | — | US | disclosed |
| US-4927830-A | HERPES, CYTOMEGALO VIRUS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1990-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829450-B2 | Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine | KDM4D, KDM4A, KDM4C | MEN1 4180/4885NPC1 4424/4885RAB9A 827/4885 |
| US-20250215009-A1 | PROCESS FOR MAKING CRYSTALLINE 2-(3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-1-(CYCLOPROPYLSULFONYL)AZETIDIN-3-YL)ACETONITRILE | PRNP, TTR, SFPQ | MEN1 2634/4885NPC1 109/4885RAB9A 1767/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | MEN1 3188/4885NPC1 4219/4885RAB9A 1829/4885 |
| US-20250205157-A1 | TOPICAL RUXOLITINIB FOAM | JAK1, BRAF, CCR8 | MEN1 2927/4885NPC1 3080/4885RAB9A 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.